NCT06925971View on ClinicalTrials.gov

A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM）

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

279

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2027

Conditions
Intracranial Arteriosclerosis
Interventions
DEVICE

Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)

Experimental Device A, a self-expanding rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)

DEVICE

Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)

Experimental Device B, a balloon-expandable rapamycin target-eluting stent (MicroPort NeuroTech, Shanghai, China)

DEVICE

Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China),

Apollo® Intracranial Artery Stent System, a balloon-expandable bare-metal stent (MicroPort NeuroTech, Shanghai, China)

Trial Locations (1)

Unknown

Shanghai Changhai Hospital, Shanghai

All Listed Sponsors
lead

MicroPort NeuroTech Co., Ltd.

INDUSTRY

NCT06925971 - A Randomized Trial of the Rapamycin Target Eluting Stent for the Treatment of Symptomatic Cerebral Artery Atherosclerotic Disease（TARGET-DREAM） | Biotech Hunter | Biotech Hunter